Literature DB >> 15805554

Therapeutic monoclonal antibodies in oncology.

Adam P Levene1, Guminder Singh, Carlo Palmieri.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15805554      PMCID： PMC1079437          DOI： 10.1177/014107680509800403

Source DB:  PubMed          Journal:  J R Soc Med        ISSN： 0141-0768            Impact factor:   18.000


× No keyword cloud information.
  57 in total

1.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

Authors:  Bertrand Coiffier; Eric Lepage; Josette Briere; Raoul Herbrecht; Hervé Tilly; Reda Bouabdallah; Pierre Morel; Eric Van Den Neste; Gilles Salles; Philippe Gaulard; Felix Reyes; Pierre Lederlin; Christian Gisselbrecht
Journal:  N Engl J Med       Date:  2002-01-24       Impact factor: 91.245

2.  Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

Authors:  Thomas E Witzig; Leo I Gordon; Fernando Cabanillas; Myron S Czuczman; Christos Emmanouilides; Robin Joyce; Brad L Pohlman; Nancy L Bartlett; Gregory A Wiseman; Norman Padre; Antonio J Grillo-López; Pratik Multani; Christine A White
Journal:  J Clin Oncol       Date:  2002-05-15       Impact factor: 44.544

3.  Phase II trial of KW2189 in patients with advanced malignant melanoma.

Authors:  Svetomir N Markovic; Vera J Suman; Allen M Vukov; Tom R Fitch; David W Hillman; Alex A Adjei; Steven R Alberts; Judith S Kaur; Theodore A Braich; John M Leitch; Edward T Creagan
Journal:  Am J Clin Oncol       Date:  2002-06       Impact factor: 2.339

Review 4.  Epidermal growth factor receptor biology (IMC-C225).

Authors:  E S Kim; F R Khuri; R S Herbst
Journal:  Curr Opin Oncol       Date:  2001-11       Impact factor: 3.645

Review 5.  Future of monoclonal antibodies in the treatment of hematologic malignancies.

Authors:  Mitchell E Reff; Kandasamy Hariharan; Gary Braslawsky
Journal:  Cancer Control       Date:  2002 Mar-Apr       Impact factor: 3.302

Review 6.  Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers.

Authors:  Lee S Rosen
Journal:  Cancer Control       Date:  2002 Mar-Apr       Impact factor: 3.302

Review 7.  Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart.

Authors:  J W Schneider; A Y Chang; T P Rocco
Journal:  Semin Oncol       Date:  2001-10       Impact factor: 4.929

8.  Cardiac dysfunction in the trastuzumab clinical trials experience.

Authors:  Andrew Seidman; Clifford Hudis; Mary Kathryn Pierri; Steven Shak; Virginia Paton; Mark Ashby; Maureen Murphy; Stanford J Stewart; Deborah Keefe
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

9.  Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

Authors:  Jeanette Lundin; Eva Kimby; Magnus Björkholm; Per-Anders Broliden; Fredrik Celsing; Viktoria Hjalmar; Lars Möllgård; Peppy Rebello; Geoff Hale; Herman Waldmann; Håkan Mellstedt; Anders Osterborg
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

10.  Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer.

Authors:  David Osoba; Dennis J Slamon; Michael Burchmore; Maureen Murphy
Journal:  J Clin Oncol       Date:  2002-07-15       Impact factor: 44.544
View more
  12 in total

1.  The role of molecular imaging in the development of dendritic cell-based cancer vaccines.

Authors:  Giovanni Lucignani; Maria Rescigno
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-07       Impact factor: 9.236

Review 2.  Monoclonal antibodies in cancer immunotherapy.

Authors:  Ilgin Kimiz-Gebologlu; Sultan Gulce-Iz; Cigir Biray-Avci
Journal:  Mol Biol Rep       Date:  2018-10-11       Impact factor: 2.316

Review 3.  Panitumumab: in the treatment of metastatic colorectal cancer.

Authors:  Sheridan M Hoy; Antona J Wagstaff
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 4.  Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.

Authors:  Michelle A Fanale; Anas Younes
Journal:  Drugs       Date:  2007       Impact factor: 9.546

5.  Direct and indirect engagement of dendritic cell function by antibodies developed for cancer therapy.

Authors:  Diana Corogeanu; Sandra S Diebold
Journal:  Clin Exp Immunol       Date:  2022-07-22       Impact factor: 5.732

6.  Furin targeted drug delivery for treatment of rhabdomyosarcoma in a mouse model.

Authors:  Katarina Hajdin; Valentina D'Alessandro; Felix K Niggli; Beat W Schäfer; Michele Bernasconi
Journal:  PLoS One       Date:  2010-05-03       Impact factor: 3.240

Review 7.  The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived?

Authors:  Barrett W Newsome; Marc S Ernstoff
Journal:  Br J Clin Pharmacol       Date:  2008-05-22       Impact factor: 4.335

Review 8.  Cancer immunotherapies revisited: state of the art of conventional treatments and next-generation nanomedicines.

Authors:  Coral García-Fernández; Anna Saz; Cristina Fornaguera; Salvador Borrós
Journal:  Cancer Gene Ther       Date:  2021-04-09       Impact factor: 5.987

Review 9.  Combining Diagnostic Imaging and Pathology for Improving Diagnosis and Prognosis of Cancer.

Authors:  Orazio Schillaci; Manuel Scimeca; Nicola Toschi; Rita Bonfiglio; Nicoletta Urbano; Elena Bonanno
Journal:  Contrast Media Mol Imaging       Date:  2019-07-01       Impact factor: 3.161

10.  The Use of Phage-Displayed Peptide Libraries to Develop Tumor-Targeting Drugs.

Authors:  Lauren R H Krumpe; Toshiyuki Mori
Journal:  Int J Pept Res Ther       Date:  2006-03-03       Impact factor: 1.931
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.